[EN] SMALL MOLECULE RAS LIGANDS<br/>[FR] LIGANDS RAS DE PETITES MOLÉCULES
申请人:UNIV COLUMBIA
公开号:WO2016176338A1
公开(公告)日:2016-11-03
The present invention provides compounds that selectively bind a RAS protein at three or more sites, which compounds selectively bind to a first site on the RAS protein that includes at least one amino acid near L56. Pharmaceutical compositions including a pharmaceutically acceptable carrier and a compound of the present invention are also provided. Methods and kits for treating or ameliorating the effects of a disease associated with altered RAS signaling in a subject are also provided. Methods, kits and compositions which include such compounds also are provided.
A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands
作者:Emma K. Grant、David J. Fallon、Michael M. Hann、Ken G. M. Fantom、Chad Quinn、Francesca Zappacosta、Roland S. Annan、Chun‐wa Chung、Paul Bamborough、David P. Dixon、Peter Stacey、David House、Vipulkumar K. Patel、Nicholas C. O. Tomkinson、Jacob T. Bush
DOI:10.1002/anie.202008361
日期:2020.11.16
termed PhABits (PhotoAffinity Bits), which utilizes a library of photoreactive fragments to covalently capture fragment–protein interactions. Hits can be profiled to determine potency and the site of crosslinking, and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is envisioned to be widely applicable to novel protein targets, identifying
Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation
作者:Qi Sun、Jason P. Burke、Jason Phan、Michael C. Burns、Edward T. Olejniczak、Alex G. Waterson、Taekyu Lee、Olivia W. Rossanese、Stephen W. Fesik
DOI:10.1002/anie.201201358
日期:2012.6.18
NMR spectroscopy was applied to discover ligands that bind to the GTPase K‐Ras and modulate the activity of the nucleotide exchange factor Sos. Structural data on how these fragment‐derived hits bind to the guanosine diphosphate–K‐Ras complex (see picture) provides a starting point for the future discovery of drugs that target K‐Ras activation and signaling.